目的探讨肝非唾液酸糖蛋白受体显像与肝储备功能关系。
Objective To investigate the relation between ASGP-R developing and the reserve function of hepar.
在过去三十多年来，已报道了许多由无唾液酸糖蛋白受体介导的肝靶向药物。
During the past more than 30 years, a lot of liver targeting conjugates mediated by ASGP-R have been prepared and reported.
去唾液酸糖蛋白受体(asgpr)是哺乳动物肝细胞表面的特异性受体，肝硬化和肝癌时asgpr水平下降。
Asialoglycoprotein receptor (ASGPR) is a specific receptor of mammalian hepatocytes. Reduction in ASGPR concentration has been proven to appear in liver cirrhosis and liver cancer.
常用的受体有去唾液酸糖蛋白受体、胰岛素受体、血管内皮细胞生长因子受体、转铁蛋白受体、甘露糖受体、表皮生长因子受体、叶酸受体等。
Asialoglycoprotein receptor, transferrin receptor and receptors for lactoferrin, insulin, epidermal growth factor, folic acid and mannose have been used in receptor-mediated gene delivery.
常用的受体有去唾液酸糖蛋白受体、胰岛素受体、血管内皮细胞生长因子受体、转铁蛋白受体、甘露糖受体、表皮生长因子受体、叶酸受体等。
Asialoglycoprotein receptor, transferrin receptor and receptors for lactoferrin, insulin, epidermal growth factor, folic acid and mannose have been used in receptor-mediated gene delivery.
应用推荐